

REPORT TO THE LEGISLATURE

**Pursuant to
P.A. 166 of 2020 Article 2,
Section 807
Hepatitis C treatment Report
4th Qtr-FY21**

Section 807: The funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment. On a quarterly basis, the department shall issue a report to the senate and house appropriations subcommittees on corrections, the senate and house fiscal agencies, and the legislative corrections ombudsman, and the state budget office, showing for the previous 4 quarters the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners that were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

QTR	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd	Total rebate expected
1st QTR FY 2021	188	312	170	\$ 2,817,371	\$ -	\$ -
2nd QTR FY 2021	185	341	171	\$ 2,675,060	\$ -	\$ -
3rd QTR FY 2021	155	460	132	\$ 2,865,132	\$ -	\$ -
4th QTR FY 2021	178	473	220	\$ 2,841,185	\$ -	\$ -

*The vendor renegotiated with the drug manufacturer to get better pricing. As a result, there are no rebates.